Joseph Nkwanyuo, MD
Internal Medicine · Randallstown, MDNPI 1194805036
Payments from drug & device makers
Across 77 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$208
- Novo Nordisk$163
- Amarin Pharma, Inc.$160
- AbbVie$140
- AstraZeneca$115
- Novartis$82
- plus $460 from 14 others
What the payments were for
- Food & beverage$1,28997%
- Education$383%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 12 | $208 |
| Novo Nordisk | 9 | $163 |
| Amarin Pharma, Inc. | 8 | $160 |
| AbbVie(2 entities) | 9 | $140 |
| AstraZeneca | 8 | $115 |
| Novartis | 4 | $82 |
| Merck | 5 | $73 |
| Lilly USA, LLC | 3 | $59 |
| Astellas Pharma US Inc | 3 | $51 |
| Kowa Pharmaceuticals America, Inc. | 3 | $40 |
| Boston Scientific | 1 | $37 |
| Gilead | 2 | $35 |
| Redhill Biopharma Inc. | 2 | $33 |
| Amgen | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Pfizer | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
How this compares
$1,327 in reported general payments places this provider in the 75th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 39 | $151,579 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 33 | $133,723 |
| JardianceEmpagliflozin | 59 | $93,732 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 33 | $45,417 |
| EliquisApixaban | 22 | $33,641 |
| XareltoRivaroxaban | 24 | $23,661 |
| JanuviaSitagliptin Phosphate | 20 | $17,142 |
| OzempicSemaglutide | 15 | $14,342 |
| MyrbetriqMirabegron | 23 | $13,801 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $12,682 |
| LinzessLinaclotide | 17 | $10,563 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,581 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,188 |
| Oxycodone Hcl | 238 | $3,946 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $3,500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $35 | $285,30272 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $208 | $99,92072 claims |
| MerckJanumet Xr, Januvia | $73 | $62,55953 claims |
| PfizerEliquis | $15 | $33,64122 claims |
| Novo NordiskOzempic | $163 | $14,34215 claims |
| Astellas Pharma US IncMyrbetriq | $51 | $13,80123 claims |
| AbbVieLinzess | $140 | $10,56317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Randallstown
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
- Mark YarchoanBaltimore$2.4M
- Marianne MannHighland$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.